BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Loh J, Davis ID, Martin JM, Siva S. Extracranial oligometastatic renal cell carcinoma: current management and future directions. Future Oncol 2014;10:761-74. [PMID: 24799057 DOI: 10.2217/fon.14.40] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Magné N, Latorzeff I. Oligometastatic renal cell carcinoma: radiotherapy as a new standard of care? Lancet Oncol 2021;22:1644-5. [PMID: 34856135 DOI: 10.1016/S1470-2045(21)00665-3] [Reference Citation Analysis]
2 Zaorsky NG, Lehrer EJ, Kothari G, Louie AV, Siva S. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. European Urology Oncology 2019;2:515-23. [DOI: 10.1016/j.euo.2019.05.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
3 Ahn T, Roberts MJ, Abduljabar A, Joshi A, Perera M, Rhee H, Wood S, Vela I. A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC). Mol Imaging Biol 2019;21:799-807. [PMID: 30617728 DOI: 10.1007/s11307-018-01307-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
4 Siva S, Jackson P, Kron T, Bressel M, Lau E, Hofman M, Shaw M, Chander S, Pham D, Lawrentschuk N, Wong LM, Goad J, Foroudi F. Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: Establishing a dose-response relationship. Radiother Oncol 2016;118:540-6. [PMID: 26873790 DOI: 10.1016/j.radonc.2016.01.027] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
5 Pitroda SP, Khodarev NN, Huang L, Uppal A, Wightman SC, Ganai S, Joseph N, Pitt J, Brown M, Forde M, Mangold K, Xue L, Weber C, Segal JP, Kadri S, Stack ME, Khan S, Paty P, Kaul K, Andrade J, White KP, Talamonti M, Posner MC, Hellman S, Weichselbaum RR. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun 2018;9:1793. [PMID: 29728604 DOI: 10.1038/s41467-018-04278-6] [Cited by in Crossref: 85] [Cited by in F6Publishing: 91] [Article Influence: 21.3] [Reference Citation Analysis]
6 Bludau F, Reis T, Schneider F, Clausen S, Wenz F, Obertacke U. [Kyphoplasty combined with intraoperative radiotherapy (Kypho-IORT). Alternative therapy for patients with oligometastatic spinal metastases]. Radiologe 2015;55:859-67. [PMID: 26420600 DOI: 10.1007/s00117-015-0018-1] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
7 Meyer E, Pasquier D, Bernadou G, Calais G, Maroun P, Bossi A, Theodore C, Albiges L, Stefan D, de Crevoisier R, Hennequin C, Lagrange J, Grellard J, Clarisse B, Licaj I, Habrand J, Carrie C, Joly F. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group. European Journal of Cancer 2018;98:38-47. [DOI: 10.1016/j.ejca.2018.04.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
8 Siva S, Callahan J, Pryor D, Martin J, Lawrentschuk N, Hofman MS. Utility of 68 Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. J Med Imaging Radiat Oncol 2017;61:372-8. [DOI: 10.1111/1754-9485.12590] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 9.8] [Reference Citation Analysis]
9 Kondo T. Treatment Overview. In: Oya M, editor. Renal Cell Carcinoma. Tokyo: Springer Japan; 2017. pp. 177-207. [DOI: 10.1007/978-4-431-55531-5_6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
10 Wei Q, He H, Lv L, Xu X, Sun W. The promising role of radiotherapy in the treatment of advanced or metastatic renal cell carcinoma: a narrative review. Transl Androl Urol 2020;9:2821-30. [PMID: 33457253 DOI: 10.21037/tau-20-1466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Reyes DK, Pienta KJ. The biology and treatment of oligometastatic cancer. Oncotarget 2015;6:8491-524. [PMID: 25940699 DOI: 10.18632/oncotarget.3455] [Cited by in Crossref: 151] [Cited by in F6Publishing: 143] [Article Influence: 25.2] [Reference Citation Analysis]
12 Brandes AA, Franceschi E. The metastatic process: a kaleidoscope of concepts. Future Oncol 2014;10:697-8. [PMID: 24799049 DOI: 10.2217/fon.14.32] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Gardner CS, Ensor JE, Ahrar K, Huang SY, Sabir SH, Tannir NM, Lewis VO, Tam AL. Cryoablation of Bone Metastases from Renal Cell Carcinoma for Local Tumor Control. J Bone Joint Surg Am 2017;99:1916-26. [PMID: 29135665 DOI: 10.2106/JBJS.16.01182] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
14 Lee J, Yoon HI, Rha SY, Hyung WJ, Lee YC, Lim JS, Kim HS, Koom WS. Integration of radiotherapy and chemotherapy for abdominal lymph node recurrence in gastric cancer. Clin Transl Oncol 2017;19:1268-75. [DOI: 10.1007/s12094-017-1665-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
15 Mery B, Rancoule C, Rowinski E, Bosacki C, Vallard A, Guy JB, Magné N. Cancer du rein et radiothérapie : radiorésistance et au-delà. Bull Cancer 2018;105 Suppl 3:S280-5. [PMID: 30595157 DOI: 10.1016/S0007-4551(18)30383-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
16 Bersanelli M, Gnetti L, Varotti E, Ampollini L, Carbognani P, Leonardi F, Rusca M, Campanini N, Ziglioli F, Dadomo CI, Pilato FP, Cortellini A, Rapacchi E, Caruso G, Silini EM, Maestroni U, Buti S. Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma. Immunotherapy 2019;11:21-35. [DOI: 10.2217/imt-2018-0097] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
17 Claeys T, Lumen N, Kumps C, Praet M, De Meerleer G, Rottey S, Ost P, Devisschere P, Villeirs G, Fonteyne V, Decaestecker K. The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies. Urol Oncol 2017;35:152.e13-22. [PMID: 28153420 DOI: 10.1016/j.urolonc.2016.10.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
18 Berghen C, Joniau S, Vulsteke C, Albersen M, Devos G, Rans K, Haustermans K, De Meerleer G. Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news. Ecancermedicalscience 2020;14:1036. [PMID: 32565889 DOI: 10.3332/ecancer.2020.1036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Siva S, Ellis RJ, Ponsky L, Teh BS, Mahadevan A, Muacevic A, Staehler M, Onishi H, Wersall P, Nomiya T, Lo SS. Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. Future Oncology 2016;12:637-45. [DOI: 10.2217/fon.16.2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
20 Iftode C, DʼAgostino GR, Tozzi A, Comito T, Franzese C, De Rose F, Franceschini D, Di Brina L, Tomatis S, Scorsetti M. Stereotactic Body Radiation Therapy in Oligometastatic Ovarian Cancer: A Promising Therapeutic Approach. Int J Gynecol Cancer 2018;28:1507-13. [PMID: 30036231 DOI: 10.1097/IGC.0000000000001324] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 5.3] [Reference Citation Analysis]